EMERGENT BIOSOLUTIONS INC (EBS) Stock Price, Quote, News and Overview
NYSE:EBS - New York Stock Exchange, Inc. - US29089Q1058 - Common Stock - Currency: USD
EBS Quote, Performance and Key Statistics
EMERGENT BIOSOLUTIONS INC
NYSE:EBS (2/4/2025, 8:04:00 PM)
After market: 10.56 -0.13 (-1.22%)10.69
+0.2 (+1.91%)
The current stock price of EBS is 10.69 USD. In the past month the price increased by 3.59%. In the past year, price increased by 576.58%.
EBS Latest News, Press Releases and Analysis
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
Africa CDC’s support for the MOSA has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of...
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to distribute...
EBS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 15.04 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About EBS
Company Profile
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 1,600 full-time employees. The company went IPO on 2006-11-15. The company is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
Company Info
EMERGENT BIOSOLUTIONS INC
300 Professional Dr
Gaithersburg MARYLAND 20879 US
CEO: Robert G. Kramer
Employees: 1600
Company Website: https://emergentbiosolutions.com/
Investor Relations: http://investors.emergentbiosolutions.com/phoenix.zhtml?c=202582&p=irol-IRHome
Phone: 12406313200
EBS FAQ
What is the stock price of EBS?
The current stock price of EBS is 10.69 USD.
What is the symbol for EMERGENT BIOSOLUTIONS INC stock?
The exchange symbol of EMERGENT BIOSOLUTIONS INC is EBS and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is EBS stock listed?
EBS stock is listed on the New York Stock Exchange, Inc. exchange.
Is EBS a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for EBS, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of EBS.
Does EBS stock pay dividends?
EBS does not pay a dividend.
When does EBS stock report earnings?
EBS will report earnings on 2025-02-20, after the market close.
What is the Price/Earnings (PE) ratio of EBS?
EBS does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.13).
What is the Short Interest ratio of EBS stock?
The outstanding short interest for EBS is 13.27% of its float.
EBS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to EBS. When comparing the yearly performance of all stocks, EBS is one of the better performing stocks in the market, outperforming 99.18% of all stocks.
EBS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EBS. Both the profitability and financial health of EBS have multiple concerns.
EBS Financial Highlights
Over the last trailing twelve months EBS reported a non-GAAP Earnings per Share(EPS) of -1.13. The EPS increased by 77.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.13% | ||
| ROE | -41.07% | ||
| Debt/Equity | 1.3 |
EBS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 74% to EBS. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 84.98% and a revenue growth 3.43% for EBS